Findings of Research Misconduct, 29278 [2016-11062]
Download as PDF
<![CDATA[
29278
Federal Register / Vol. 81, No. 91 / Wednesday, May 11, 2016 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Kenneth Walker, Ph.D., University of
Pittsburgh: Based on the admission of
the Respondent, ORI found that Dr.
Kenneth Walker, former postdoctoral
fellow, Department of Pediatrics,
University of Pittsburgh (UP), engaged
in research misconduct in research
supported by National Institute of
Diabetes and Digestive and Kidney
Diseases (NIDDK), National Institutes of
Health (NIH), grant R01 DK081128.
ORI found that Respondent engaged
in research misconduct by falsifying
and/or fabricating data that were
included in the following two (2)
publications, one (1) submitted
manuscript, and two (2) grant
applications submitted to NIDDK, NIH:
• ‘‘Deletion of fibroblast growth factor
receptor 2 from the peri-wolffian duct
stroma leads to ureteric induction
abnormalities and vesicoureteral
reflux.’’ PLoS One 8(2):e56062, 2013
(hereafter referred to as ‘‘PLoS 2013’’)
• ‘‘Fgfr2 is integral for bladder
mesenchyme patterning and
function.’’ Am J Physiol Renal
Physiol. 308(8):F888–98, 2015 Apr 15
(hereafter referred to as ‘‘AJPRP
2015’’)
• Unpublished manuscript submitted to
PLoS One (hereafter referred to as the
‘‘Manuscript’’)
• R01 DK104374–01A1
• R01 DK109682–01
Specifically, ORI found that
Respondent falsified and/or fabricated
quantitative real-time polymerase chain
reaction (qPCR) data to demonstrate a
statistically significant or ‘‘trend’’ of
statistical difference in the expression of
renal or bladder urothelium and muscle
developmental markers between control
and experimental (mutant) mice, when
there was none. The false qPCR data
were reported in:
• PLoS 2013: Figure 2E
• AJPRP 2015: Figures 1E, 4C, 7G, 7J,
8F, 12A
• Manuscript: Figures 1C, 4C
• R01 DK104374–01A1: Figure 14E and
text on pages 41, 42, 45
• R01 DK109682–01: Figures 10G and
11 and text on pages 43 and 45
mstockstill on DSK3G9T082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:20 May 10, 2016
Jkt 238001
Dr. Walker has entered into a
Voluntary Settlement Agreement
(Agreement) and has voluntarily agreed:
(1) To have his research supervised
for a period of three (3) years, beginning
on April 14, 2016; Respondent agrees
that prior to submission of an
application for U.S. Public Health
Service (PHS) support for a research
project on which the Respondent’s
participation is proposed and prior to
Respondent’s participation in any
capacity on PHS-supported research,
Respondent shall ensure that a plan for
supervision of Respondent’s duties is
submitted to ORI for approval; the
supervision plan must be designed to
ensure the scientific integrity of
Respondent’s research contribution;
Respondent agrees that he shall not
participate in any PHS-supported
research until such a supervision plan is
submitted to and approved by ORI;
Respondent agrees to maintain
responsibility for compliance with the
agreed upon supervision plan;
(2) that any institution employing him
shall submit, in conjunction with each
application for PHS funds, or report,
manuscript, or abstract involving PHSsupported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract;
(3) to exclude himself from serving in
any advisory capacity to PHS including,
but not limited to, service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant for
period of three (3) years, beginning on
April 14, 2016; and
(4) to the retraction and/or correction
of the PLoS 2013 and AJPRP 2015
publications, as determined by the
corresponding author.
FOR FURTHER INFORMATION CONTACT:
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
Kathryn Partin,
Director, Office of Research Integrity.
[FR Doc. 2016–11062 Filed 5–10–16; 8:45 am]
BILLING CODE 4150–31–P
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the National Coordinator for
Health Information Technology;
Announcement of Requirements and
Registration for ‘‘Move Health Data
Forward Challenge’’
Office of the National
Coordinator for Health Information
Technology, HHS.
ACTION: Notice.
AGENCY:
The Move Health Data
Forward Challenge aims to incentivize
participants to create an application
programming interface (API) solution
that utilizes the implementation
specifications developed by the HEART
Workgroup (Heart WG) to enable
individuals to securely authorize the
movement of their health data to
destinations they choose. The statutory
authority for this Challenge is Section
105 of the America COMPETES
Reauthorization Act of 2010 (Pub. L.
111–358).
DATES:
Phase 1:
• Challenge launch: May 10, 2016
• Submissions due: September 8,
2016
• Evaluation period: September 9—
October 14, 2016
• Phase 1 winners announced:
October 31, 2016
Phase 2:
• Prototyping period begins: October
31, 2016
• Submissions due: January 12, 2017
• Evaluation period: January 12—
February 10, 2017
• Phase 2 winners announced:
February 23, 2017
Phase 3:
• Scaling period begins: February 23,
2017
• Submission period ends: May 1,
2017
• Phase 3 winners announced: May
31, 2017
FOR FURTHER INFORMATION CONTACT:
Caroline Coy, caroline.coy@hhs.gov
(preferred), 202–720–2932.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Award Approving Official
Karen DeSalvo, National Coordinator
for Health Information Technology.
Subject of Challenge
ONC participated with a number of
security, privacy and health Information
technology (health IT) stakeholders to
launch the HEART WG. The HEART
WG was developed to expedite the
process of gathering representatives
from many different health-related
E:\FR\FM\11MYN1.SGM
11MYN1
]]>Agencies
[Federal Register Volume 81, Number 91 (Wednesday, May 11, 2016)]
[Notices]
[Page 29278]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-11062]
[[Page 29278]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has taken final action in the following case:
Kenneth Walker, Ph.D., University of Pittsburgh: Based on the
admission of the Respondent, ORI found that Dr. Kenneth Walker, former
postdoctoral fellow, Department of Pediatrics, University of Pittsburgh
(UP), engaged in research misconduct in research supported by National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),
National Institutes of Health (NIH), grant R01 DK081128.
ORI found that Respondent engaged in research misconduct by
falsifying and/or fabricating data that were included in the following
two (2) publications, one (1) submitted manuscript, and two (2) grant
applications submitted to NIDDK, NIH:
``Deletion of fibroblast growth factor receptor 2 from the
peri-wolffian duct stroma leads to ureteric induction abnormalities and
vesicoureteral reflux.'' PLoS One 8(2):e56062, 2013 (hereafter referred
to as ``PLoS 2013'')
``Fgfr2 is integral for bladder mesenchyme patterning and
function.'' Am J Physiol Renal Physiol. 308(8):F888-98, 2015 Apr 15
(hereafter referred to as ``AJPRP 2015'')
Unpublished manuscript submitted to PLoS One (hereafter
referred to as the ``Manuscript'')
R01 DK104374-01A1
R01 DK109682-01
Specifically, ORI found that Respondent falsified and/or fabricated
quantitative real-time polymerase chain reaction (qPCR) data to
demonstrate a statistically significant or ``trend'' of statistical
difference in the expression of renal or bladder urothelium and muscle
developmental markers between control and experimental (mutant) mice,
when there was none. The false qPCR data were reported in:
PLoS 2013: Figure 2E
AJPRP 2015: Figures 1E, 4C, 7G, 7J, 8F, 12A
Manuscript: Figures 1C, 4C
R01 DK104374-01A1: Figure 14E and text on pages 41, 42, 45
R01 DK109682-01: Figures 10G and 11 and text on pages 43 and
45
Dr. Walker has entered into a Voluntary Settlement Agreement
(Agreement) and has voluntarily agreed:
(1) To have his research supervised for a period of three (3)
years, beginning on April 14, 2016; Respondent agrees that prior to
submission of an application for U.S. Public Health Service (PHS)
support for a research project on which the Respondent's participation
is proposed and prior to Respondent's participation in any capacity on
PHS-supported research, Respondent shall ensure that a plan for
supervision of Respondent's duties is submitted to ORI for approval;
the supervision plan must be designed to ensure the scientific
integrity of Respondent's research contribution; Respondent agrees that
he shall not participate in any PHS-supported research until such a
supervision plan is submitted to and approved by ORI; Respondent agrees
to maintain responsibility for compliance with the agreed upon
supervision plan;
(2) that any institution employing him shall submit, in conjunction
with each application for PHS funds, or report, manuscript, or abstract
involving PHS-supported research in which Respondent is involved, a
certification to ORI that the data provided by Respondent are based on
actual experiments or are otherwise legitimately derived and that the
data, procedures, and methodology are accurately reported in the
application, report, manuscript, or abstract;
(3) to exclude himself from serving in any advisory capacity to PHS
including, but not limited to, service on any PHS advisory committee,
board, and/or peer review committee, or as a consultant for period of
three (3) years, beginning on April 14, 2016; and
(4) to the retraction and/or correction of the PLoS 2013 and AJPRP
2015 publications, as determined by the corresponding author.
FOR FURTHER INFORMATION CONTACT: Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240)
453-8200.
Kathryn Partin,
Director, Office of Research Integrity.
[FR Doc. 2016-11062 Filed 5-10-16; 8:45 am]
BILLING CODE 4150-31-P
